Skip to main content
Ryan Sullivan, MD, Oncology, Cambridge, MA

RyanJSullivanMD

Oncology Cambridge, MA

Physician

Dr. Sullivan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Sullivan's full profile

Already have an account?

  • Office

    330 Mount Auburn St
    Cambridge, MA 02138
    Phone+1 617-499-5112
    Fax+1 617-575-8608

Education & Training

  • Beth Israel Deaconess Medical Center
    Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
  • Mount Auburn Hospital
    Mount Auburn HospitalResidency, Internal Medicine, 2001 - 2004
  • Uconn School Of Medicine
    Uconn School Of MedicineClass of 2001

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2004 - 2025
  • NH State Medical License
    NH State Medical License 2024 - 2024
  • ME State Medical License
    ME State Medical License 2020 - 2021
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Publisher Correction: Robust Prediction of Response to Immune Checkpoint Blockade Therapy in Metastatic Melanoma  
    Genevieve Boland, Ryan J Sullivan, Keith Flaherty, Nature
  • Robust Prediction of Response to Immune Checkpoint Blockade Therapy in Metastatic Melanoma  
    Ryan J Sullivan, Genevieve Boland, Keith Flaherty, Nature

Lectures

  • Debate: Immunotherapy Targeted Therapy Versus Immunotherapy Sequencing — Immunotherapy Sequencing... 
    ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019
  • Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Other

Authored Content

  • Forestalling BRAF-Inhibitor Resistance in a Shocking WayJuly 2018
  • Corrigendum to “Rechallenge with BRAF-Directed Treatment in Metastatic Melanoma: A Multi-Institutional Retrospective Study*” [Eur J Cancer 91 (2018) 116–124]March 2018
  • Rechallenge with BRAF-Directed Treatment in Metastatic Melanoma: A Multi-Institutional Retrospective Study☆February 2018

Press Mentions

  • Breakthrough Study Shows Promise for mRNA Cancer Vaccines
    Breakthrough Study Shows Promise for mRNA Cancer VaccinesApril 17th, 2023
  • In What Could Be a 'Big Shift' for Cancer Treatment, mRNA Vaccine Shows Promise Against Melanoma
    In What Could Be a 'Big Shift' for Cancer Treatment, mRNA Vaccine Shows Promise Against MelanomaApril 16th, 2023
  • Study Suggests Narrow Excision Margins Safe in Early Melanoma Resection
    Study Suggests Narrow Excision Margins Safe in Early Melanoma ResectionApril 14th, 2023
  • Join now to see all